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Abstract Active immunotherapy forcancer isanaccepted
treatmentmodalityaimingtoreinforcetheT-cellresponseto
cancer. T-cell reactivity is measured by various assays and
used to guide the clinical development of immunothera-
peutics. However, data obtained across different institutions
may vary substantially making comparative conclusions
difﬁcult. The Cancer Immunotherapy Immunoguiding Pro-
gramorganizesproﬁciencypanelstoidentifykeyparameters
inﬂuencing the outcome of commonly used T-cell assays
followed by harmonization. Our successes with IFNc-ELI-
SPOT and peptide HLA multimer analysis have led to the
current study on intracellular cytokine staining (ICS). We
report the results of three successive panels evaluating this
assay. At the beginning, 3 out of 9 participants (33 %) were
able to detect [6 out of 8 known virus-speciﬁc T-cell
responses in peripheral blood of healthy individuals. This
increased to 50 % of the laboratories in the second phase.
The reported percentages of cytokine-producing T cells by
the different laboratories were highly variable with coefﬁ-
cientsofvariationwellover60 %.Variabilitycouldpartially
be explained by protocol-related differences in background
cytokine production leading to sub-optimal signal-to-noise
ratios. The large number of protocol variables prohibited
identiﬁcationofprimeguidelinestoharmonizetheassays.In
addition, the gating strategy used to identify reactive T cells
had a major impact on assay outcome. Subsequent harmo-
nization of the gating strategy considerably reduced the
variabilitywithinthegroupofparticipants.Inconclusion,we
propose that ﬁrst basic guidelines should be applied for
gating in ICS experiments before harmonizing assay proto-
col variables.
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Introduction
The immune system is an important component in con-
trolling cancer development. Tumor-speciﬁc T cells make
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DOI 10.1007/s00262-012-1282-9a major contribution to this effect. Immunosuppressed
individuals, such as transplant recipients, have a substan-
tially elevated risk of developing malignancy [1], and there
exists a strong association between an intratumoral T-cell
inﬁltrate and increased overall survival in many types of
cancer [2]. Reinforcement of the adaptive immune
response in patients with cancer through immunotherapy
has now developed into an accepted modality, either as
standalone therapy or in combination with standard strat-
egies such as surgery, radiotherapy and chemotherapy.
Recently, two immunotherapeutics were approved by the
food and drug administration (FDA). One is the vaccine
Sipuleucel-T in prostate cancer and the other the anti-
CTLA-4 monoclonal antibody Ipilimumab in melanoma
[3, 4]. Although efﬁcacy of immunotherapeutic interven-
tion is a clinical parameter, there is an urgent need for
biomarkers that allow the selection of patients for immu-
notherapy or that predict for beneﬁt early enough to allow
treatment decisions to be made. These biomarkers need to
detect changes in the patient’s immune response and are
likely to reﬂect parameters associated with the mechanism
of action identiﬁed in preclinical models.
For rational development of T-cell immunotherapeutics,
robustandsensitiveimmunologicalassaysabletodetermine
thequalityandquantityoftumor-speciﬁc Tcellsare critical.
The most commonly used assays are IFNc enzyme-linked
immunospot (ELISPOT), HLA multimer staining and the
intracellular cytokine staining (ICS) assay. The latter two
are ﬂow cytometry based and can provide detailed infor-
mation at the single cell level. Despite the fact that these
assays are widely used, it has been difﬁcult to show a direct
correlation between T-cell response and clinical course in
many studies. Reasons for this are the generally low number
of clinical responses observed and/or incomplete immuno-
monitoring of therapy-induced changes of the immune
system [5,6]. Furthermore, it isalso difﬁcult to base product
development ondirect interpretation ofpublishedstudies,as
the methods vary widely between institutes and this is
exacerbated by the lack of reference samples for quality
control. One way to overcome this heterogeneity is to rig-
orously standardize assays similar to the approach taken in
the HIV vaccination ﬁeld [7, 8] or to use a central laboratory
[9]. The CIMT Immunoguiding Program (CIP) is an Euro-
pean working group that has taken the approach of opti-
mizing and harmonizing T-cell assays through iterative
proﬁciency panels, in which laboratories measure T-cell
reactivities in the same cell samples [10]. Our goal is to
improve comparability of immune data generated by the
participating groups. During the last 6 years, twelve proﬁ-
ciency panels have been conducted by CIP, following this
multistep approach. Using some standardized reagents (i.e.,
peptides or HLA-peptide multimers), but allowing each
center to use its own protocol, parameters were identiﬁed
that had a major inﬂuence on assay outcome. In further
iterations, participants were asked to perform the assay
again, using the harmonized protocol. This straightforward
approach resulted not only in improved comparability and
reproducibility of T-cell assays, but also offered regular
performance feedback to participants and helps in estab-
lishing speciﬁc assay benchmarks [11–13].
Here, we describe the results of a series of three con-
secutive ICS proﬁciency panels. The ﬁrst two panels
showed that culture medium and background staining
inﬂuence assay outcome, similar to observations from the
other proﬁciency panels [12, 13]. These panels also
revealed a second level of variability resulting from dif-
ferences in data analysis. A third in silico panel demon-
strated that this is a key factor in ICS analysis and that
harmonization at the level of data analysis is a pre-requisite
to identify protocol-speciﬁc parameters inﬂuencing assay
performance and ultimately to decrease variability of
results generated across institutions.
Materials and methods
Structured information is provided according to the Mini-
mal Information About T-cell Assays Reporting Frame-
work for human T-cell assays [14, 15].
Samples
Selection and shipment of Peripheral Blood Mononuclear
Cells (PBMC) samples
Buffy coats of 7 HLA-A2-positive healthy blood donors
were obtained from Sanquin Blood Donor Bank in Leiden,
the Netherlands. All subjects had signed an informed
consent. PBMC were processed within 24 h and isolated
using Ficoll density gradient centrifugation, washed with
phosphate-buffered saline (PBS), resuspended in cold Fetal
Calf Serum (FCS; PAA Laboratories, Pasching, Austria)
and cooled on ice for 15 min. After dropwise addition in a
1:1 ratio of freezing medium, consisting of 80 % FCS and
20 % DMSO (Sigma, St Louis, MO, USA), the PBMC
were cryopreserved (12.4, 10.0, 10.0, 15.3, 13.6, 15.3 and
13.0 million PBMC per ml per vial for the buffy coats 1–7,
respectively) using an automated controlled rate freezer
(Cryosolutions, ’s-Hertogenbosch, the Netherlands) and
stored in equal aliquots in a vapor-phase liquid nitrogen
vessel until use. The handling and storage of the PBMC
were done according to the standard operation procedures
(SOPs) of the Leiden department of Oncology by trained
personnel. Cryopreserved PBMC (two vials from each
donor) were transported to the participants on dry ice
(minimal 5 kg/box), within 4 months after PBMC isolation
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123and subsequent storage. Samples reached the participating
laboratory within 2 days after shipment and upon arrival
were stored in liquid nitrogen as agreed by the panel
guideline.
Antigens
To quantify CD8? T-cell responses by ICS, reactivity to
FLU58–66 (GILGFVFTL) from Inﬂuenza Matrix 1 protein
and CMV pp65495–503 (NLVPMVATV) from human
cytomegalovirus was assessed. Peptides were centrally
synthesized with[95 % purity [16], dissolved in PBS with
2 % DSMO at 1 mg/ml, and 20 ll aliquots was shipped to
the participants on dry ice with the cryopreserved PBMC
and stored at -20 C. PHA (HA16; Murex BioTech, Kent,
UK) was taken along as a positive control in the pre-
screening ELISPOT assay.
Assays and data acquisition
Pre-screening to identify donors with FLU- and/or
CMV-speciﬁc CD8? T cells
Pre-screening was conducted within 1 month after cryo-
preservation by the central laboratory at the Leiden
department of Oncology by IFNc-ELISPOT assay accord-
ing to the local SOPs, in conformity with CIP guidelines
(10) (http://www.cimt.eu/workgroup/CIP). PBMC from the
7 buffy coats were thawed (using cold IMDM according to
the local SOP), counted (viable and death cells by trypan
blue staining), resuspended in 10 ml of IMDM (Lonza,
Verviers, Belgium), 100 U/ml penicillin/100 lg/ml strep-
tomycin (Lonza), 25 mM b-mercaptoethanol (Sigma) and
2 mM glutamine (Lonza) (i.e., complete IMDM), supple-
mented with 10 % heat-inactivated human AB serum
(Greiner, Alphen aan den Rijn, the Netherlands). Cells (1–2
9 10
6/ml) were rested at 37 C, 5 % CO2 and 92 % over-
night (18 h) in a 50-ml tube, with the cap loosened for gas
exchange. The recovery of viable cells immediately after
thawing ranged between 81.3 and 148.5 % (average 100 %,
median 100 %, coefﬁcient of variation (CV) value 31 %),
after resting viable cells averaged at 61.1 %, median
61.6 % and CV value 22 % of input number. The ELISPOT
assay was conducted in triplicate wells (500,000 c/w)
according to our publicly available SOP (http://www.
cimt.eu/dl/sop_elispot.pdf), except that ELISPOT plates
were blocked and PBMCs resuspended (after the overnight
resting phase) in complete IMDM with 10 % FCS insteadof
X-Vivo 15 medium. Plates were dried and measured by
ELISPOT reader (BioSys 5000; software version 10.8). The
settings of this ELISPOT reader were as follows: the spot
size from 65 to 400, the circularity of the spot 2, the slope
of the spot intensity medium and the sensitivity 81 %.
A positive response had to fulﬁll the criteria established in
CIP ELISPOT panels [12]: signiﬁcantly higher spot counts
in the triplicate antigen-stimulated cell samples (experi-
mental wells) than in medium only (triplicate control wells)
following a two-sided Student’s t test (p B 0.05), the
average spot number in the experimental wells beingat least
threefold that of the control wells. The ELISPOT assay was
conducted twice for all 7 donors, and the results are shown
in Online resource 1. For the proﬁciency panel, 5 donors
were selected: buffy coat 1 [assigned as donor 1 (D1)] and
buffy coats 4–7 [assigned as donors 2–5 (D2–D5), respec-
tively]. A total of 8 responses were identiﬁed: 3 donors (D2,
D3 and D5) responded to the HLA-A*0201-restricted CMV
peptide and all 5 donors harbored T cells against the HLA-
A*0201-restricted FLU peptide.
Design of the ICS proﬁciency panels
The ICS proﬁciency panels were conducted in a multistep
(phase) approach (Online resource 2). Nine laboratories
from 3 European countries (Germany, the Netherlands and
UK) participated in the ﬁrst panel. All laboratories were
asked to determine the frequency of IFNc-producing
CD8? T cells in the provided 5 PBMC samples (by using
only one vial) with their own ICS protocol and reagents
within 2 months upon sample receive. Participants reported
the following: (1) thawing conditions, (2) cell recovery
with or without allowing the cells to rest for a certain time
and at a certain temperature (i.e., resting phase), (3) num-
ber of cells used per test condition, (4) medium (5) serum
used in the test, (6) peptide concentration to stimulate the
PBMC, (7) duration of activation, (8) reagent to lyse/ﬁx the
cells, (9) reagent to prevent cytokine secretion, (10) reagent
to permeabilize cells, (11) antibody combination (amount,
clone, company and ﬂuorescent label), (12) duration and
conditions of staining, (13) type of ﬂow cytometer used,
(14) compensation method, (15) software, (16) number of
lymphocytes acquired, (17) number and percentages of
CD8? T cells acquired and ﬁnally (18) the number (and %)
of IFNc-producing CD8? T cells upon peptide stimulation
as determined by the participant (Online resource 3A and
4A). The results of this ﬁrst phase were used to identify the
key factors inﬂuencing the assay performance.
In the second phase, aliquots of the same PBMC sam-
ples (stored for 16 months at the participating laboratory
sites) were re-tested using mandatory parameters that were
deduced from the ﬁrst step. Six participant laboratories
reported data as in phase 1, including resting time; how-
ever, thawing conditions (point 1) and cell recovery (point
2) were not collected again (Online resource 3B and 4A).
We identiﬁed that the participants’ gating strategy was a
major assay variable. Therefore, in a third panel phase, all
participants analyzed a set of identical ﬂow cytometry
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123standard (FCS) format data ﬁles 3.0, chosen from the
dataset of one laboratory from panel phase 2. From each
donor, the data of the non-stimulated, the FLU- and CMV-
stimulated PBMC sample were provided. The participants
(n = 10) analyzed the 9 FCS ﬁles and reported the results
as described under points 16–18 (in silico ICS panel).
Three laboratories undertook re-analysis of the FCS ﬁles
using ﬁxed gating instructions to harmonize the outcome.
Data analysis and interpretation
Central analysis of the ICS panels at the Leiden department
of Oncology used the numerical data reported by the par-
ticipants. In the ﬁrst phase, background staining (i.e., per-
centage of IFNc? CD8? lymphocytes of the negative
control) was subtracted from the experimental wells (per-
centage of IFNc? CD8? lymphocytes in the test well) to
obtain the antigen-speciﬁc CD8? T-cell frequencies. For
the second and third phases, the percentages of speciﬁc
cytokine-secreting cells were calculated in the CD3? CD4-
negative subset. Gating results, provided in a ppt or pdf ﬁle,
were subjected to a visual inspection. In the second ICS
panel, the acquired events in the FCS ﬁles were also cen-
trally analyzed by a single operator at LUMC [13] and re-
assessed independently by a second experienced evaluator.
A positive response against FLU or CMV was pre-deﬁned
as at least twice the background staining and with a clearly
visible population of events. Subgroup analysis was per-
formed only when both arms comprised almost equal
numbers of participating laboratories to allow for statistical
testing (i.e., by Mann–Whitney test). Intercenter variability
was evaluated by calculating the coefﬁcients of variation
(% CV = SD/mean 9 100 %).
Laboratory environment
The pre-screening by IFNc-ELISPOT was performed in a
central laboratory that does not operate under GLP, follow-
ing SOPs and using trained staff. The central laboratory has
participated in all CIP proﬁciency panels (http://www.cimt.
eu/workgroups/cip/), as well as in IFNc-ELISPOT panels of
the Cancer Immunotherapy Consortium [17, 18], to validate
its SOPs. Participating laboratories followed their own
established protocol for the ICS assay with previous expe-
rience ranging between one and 15 years.
Results
Phase 1 proﬁciency panel for ICS
In this ﬁrst step, the participants (n = 9) used their own
ICS protocol for the detection of antigen-speciﬁc IFNc-
producing CD8? T cells (i.e., against FLU and CMV) in
the 5 pre-selected donors and reported the responses
detected (Online resource 2). Seven participants used
unstimulated PBMC (medium only) as a negative control
sample. One laboratory used isotype antibody staining and
another laboratory ﬂuorescence minus one (FMO, staining
of the cells with all antibodies except anti-IFNc) for the
determination of background staining. Of note, in all 3
panel phases, each participant applied the same gate set-
tings within one donor. Most of the participants also
applied the same gate settings to all the donors tested in
one experiment. Some participants used different gate
settings between donors in order to optimize the signal-to-
background ratio. However, this did not translate into
better or worse capacity to detect a response. Only 1 out of
9 laboratories detected all 8 responses and 3 laboratories
detected 6/8 or 7/8 responses (Table 1, phase 1). The fre-
quencies of IFNc-positive cells reported—after subtraction
of the negative control sample value—varied enormously
Table 1 Performance per participant and testing phase
Laboratory ID Phase 1 Phase 2 Phase 2
central analysis
5 8 n.t. n.t.
8 753
9 788
1 0 666
13 5 n.t. n.t.
1 5 575
2 2 275
2 4 333
26 0 n.t. n.t.
Total to be detected 8 8 8
The performance of each participant is depicted for the ICS proﬁ-
ciency panel phases 1 and 2 (and after central analysis of the phase 2
FCS ﬁles). The numbers indicate the number of positive T-cell
responses out of a total of 8 reactivities. n.t. is not tested as this
laboratory was not participating in the indicated phase
Fig. 1 Assay variables inﬂuencing the test performance in phase 1.
a Analysis plots of the same sample (i.e., donor 3 tested for FLU) are
shown for all 9 participants as indicated by ID number, demonstrating
the variety in frequencies of IFNc-producing CD8? T cells and in the
gating strategies used. b The average frequency (?SD; 9 laboratories)
of IFNc-producing CD8? T cells is depicted for each donor (D) in the
negative control samples (black bars) and after stimulation with the
CMV (left) or FLU (right) peptides (white bars). c The frequency of
IFNc-producing CD8? T cells after stimulation with CMV (left)o r
FLU (right) is plotted according to the use of IMDM (4 participants,
white boxes) or other media (5 participants, gray boxes) in the ICS
assay for all 5 donors (D). Shown are the median, interquartile range
and SD. Signiﬁcant differences as determined by Mann–Whitney test
are depicted. d Examples of the gating strategy applied for the
detection of the IFNc-producing CD8? T cells. Some participants did
not analyze the whole IFNc-producing population, but gated through
the positive cell population
c
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123within the group. CV values ranged from 69 to 285 % for
the individual donors (Online resource 4B). Exemplary
individual plots and the gating strategy are shown for D3
tested with the inﬂuenza peptide (FLU) for all 9 laborato-
ries participating in this ﬁrst phase (Fig. 1a). For each
donor, the frequency of IFNc-positive CD8? T cells in the
control and peptide-stimulated samples is shown in Fig. 1b
as an average of all laboratories. Wide variability in the
detection of the lower frequency events was the major
contributor to the large standard deviation (SD). The fre-
quencies of antigen-speciﬁc T cells ranged from at least a
14-fold difference for D5 against FLU (CV = 136 %) up
to a 142-fold difference in frequency for D5 against CMV
(CV = 262 %). We further observed substantial variability
in the background staining within the same donor between
the different laboratories and also between the 5 donors
B
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123tested by the same participating laboratory. As background
was subtracted from the positive events, high background
increased the risk of missing a response. The detection of
responses (n = 8; 39 CMV and 59 FLU) was signiﬁcantly
better when the background was below the average back-
ground value (0.118 %) of the whole group (p = 0.003;
Fig. 2).
In order to identify critical parameters responsible for
variability, we then focused on the differences in the assay
protocols used by the participating laboratories. A total of
18 different parameters were collected and analyzed
(Online resource 3A and 4A), and for some parameters, we
were able to stratify results into 2 subgroups containing
similar number of laboratories per arm. The activation time
(i.e., 5–6 h vs. overnight accumulation of IFNc) did not
inﬂuence performance. There was extensive variability in
the number of cells recovered after thawing but this did not
affect the assay performance as most laboratories used 1–2
million viable cells per donor–antigen combination, which
may have compensated for initial cell loss. It appears that
the medium (IMDM in 4 laboratories vs. another medium
in 5 laboratories) inﬂuences outcome and speciﬁcally
IMDM appeared to reduce the frequency of antigen-spe-
ciﬁc T cells detected (Fig. 1c).
Central review of the ﬂow cytometry plots revealed a
high diversity in the gating strategies used by the par-
ticipants (Fig. 1a). A surprising observation was that some
laboratories missed part of the IFNc-producing population
due to a tight gating on the CD8-high population
(Fig. 1d).
Phase 2 proﬁciency panel for ICS
A guideline was provided for this second step with three
mandatory requirements (Online resource 2). All 6 partic-
ipants had to use the same X-Vivo 15 medium, following
the results from our previous IFNc-ELISPOT panels [12,
18]. Laboratories had to stain for CD3, CD4 and CD8 and
to gate on the CD3? CD4-negative cell population to
include the CD8dim population (Fig. 3a). The third
requirement was to use non-stimulated PBMC as a nega-
tive control sample. The laboratories were asked to use the
second PBMC vial of each of the 5 donors (Table 1, phase
2; Online resource 3B and 4A). The overall results for all
laboratories per donor–antigen combination are shown in
Fig. 3b. Harmonization resulted in a substantial decrease in
variability for some donor–antigen combinations for those
laboratories participating in both panels (Fig. 3c, Online
resource 4B and 4C); however, the CV values still
remained high and above 60 %. Central analysis of the
participants’ individual FCS ﬁles did not result in an
increased detection rate or lower CV values, indicating that
the gating strategy is not the only parameter of substantial
inﬂuence on assay outcome (Table 1 and data not shown).
The relatively small number of participating laboratories
did not allow us to further characterize the protocol
parameters responsible for this variability, and larger
panels are needed to address this question.
Phase 3 in silico proﬁciency panel to harmonize
the gating strategy
In order to eliminate the role of the wet laboratory and to
be able to focus on the impact of gating and data analysis,
we undertook a multicentre in silico panel (Online resource
2). All 10 participants received the FCS ﬁles of 3 donors
(D1, D2 and D5) generated by one of the participating
laboratories during the second ICS proﬁciency panel with
one high (C1 %), one intermediate (C0.1 and\1 %) and
3 low (\0.1 %) frequency reactivities observed by ICS and
included the non-stimulated (medium) and stimulated
PBMC samples. Participants analyzed the FCS ﬁles
according to the same gating strategy that was mandated
during the second testing phase (Online resource 4A). All
but one participant followed the gating instructions. We
found that different approaches were used before the
lymphocyte population was gated, in particular exclusion
of the doublets or time versus count plot. All 10 labora-
tories plotted FSC versus SSC to gate on the lymphocytes.
Subsequent gating on the CD3? T cells varied from using
histograms or two-dimensional dot plots (CD3 vs. CD4 or
CD3 vs. FSC). Following the CD3 selection, 6 laboratories
plotted CD4 versus CD8 to gate on the CD3? CD4-
population, whereas three laboratories plotted the CD3?
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Fig. 2 High background staining decreased ability to detect responses
in phase 1. The detection (i.e., frequency of IFNc-producing speciﬁc
CD8?TcellsafterFLUorCMVpeptidestimulation)isshownonlyfor
the positive donor–antigen combinations versus a low or high
background in the corresponding negative control sample. The
background was classiﬁed as low (n = 59) or high (n = 13) based on
the average background value (0.118 %) measured in all negative
control samples (n = 72) accumulated from all participants
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123population in CD3 versus CD4. Then, all laboratories
plotted the CD3? CD4-negative population against IFNc.
Despite the set gating instructions, the measurement of the
IFNc-positive cells varied between the laboratories (Online
resource 5A). Central visual analysis of all dot plots
revealed that (1) the CD8dim population was still not
completely included by 4 laboratories and (2) some of the
participants used very tight gates close to the IFNc-nega-
tive cell population, thereby increasing the background
staining in the medium control sample. This affected sen-
sitivity, as the data in Fig. 4 demonstrate that the signal-to-
noise ratio decreased and this is reﬂected in an inability to
detect low-frequency responses (p\0.001). To conﬁrm
this observation, participants using a sub-optimal gating
strategy were asked to re-analyze the same FCS ﬁles with
improved gating. This re-analysis allowed all three labo-
ratories to detect (most of the) low-frequency responses
against the inﬂuenza peptide with a decrease in the CV
values for all donor–antigen combinations below 30 %
(Fig. 5; Online resource 5B). The most common ﬁndings/
errors and recommendations for gating are given in
Table 2. In conclusion, this in silico ICS gating panel
demonstrated that part of the huge variation in the detec-
tion rates and in the frequencies of cytokine-producing T
cells between different laboratories is generated at the level
of the analysis. We conclude that the gating strategies must
be harmonized ﬁrst for any attempt at identifying wet
laboratory contributors on ICS outcome to be successful.
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a The gating instructions provided to the participants for the second-
phase ICS proﬁciency panel. First, the lymphocytes are gated (R1),
then the CD3 population (R2), followed by plotting CD4 versus CD8
to gate on the CD8 (including the CD8dim) cells (R3), which is called
the CD3? CD4- cell population, and ﬁnally the IFNc-producing
CD3? CD4- T cells can be gated. b The average frequency (?SD)
of IFNc-producing CD3? CD4- T cells is depicted for each donor
(D) in the negative control samples (black bars) and after stimulation
with the CMV (top) or FLU (bottom) peptide (white bars). c The CV
values per donor (D)–antigen (CMV or FLU) combination are
depicted for those 6 laboratories participating in both phases 1 (white
bars) and 2 (black bars)
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123Discussion
Multiparameter ﬂow cytometry such as the intracellular
cytokine staining assay allows the simultaneous assessment
of multiple facets of the immune response against a certain
antigen. Even more than surface staining, the ICS assay
comprises a number of steps that all bear potential
inﬂuence on the data produced: these include medium,
stimulation protocol, staining protocol, instrumental set up,
use of negative and positive control samples, number of
cells for staining and acquisition, and not the least strate-
gies applied to analyze the results by computer software.
Several groups have already reported parameters that might
be important for the sensitivity of the intracellular staining
assay and have proposed standardized protocols [8, 9, 19–
25]. However to date, no harmonization has taken place
that allows interlaboratory comparison.
In an effort to harmonize ICS, the CIP conducted three
consecutive proﬁciency panels. In phases 1 and 2, we
identiﬁed that the choice of test medium and the level of
background staining inﬂuenced the test performance, in
line with previous observations for the ELISPOT assay in
our proﬁciency panels [11–13]. Harmonization of these
parameters partly resulted in a decrease in interlaboratory
CV values. Moreover, evaluation of these 2 phases sug-
gested that for ICS, a critical aspect is the choice of the
gating strategy. We chose to assess this by eliminating the
inﬂuence of the wet laboratory element of the assay and
undertook an in silico panel, where participants were asked
to analyze previously acquired data from one laboratory.
This successfully allowed us to harmonize the gating
strategy and resulted in a CV value below 30 %. The most
important steps were (1) the inclusion of the CD8dim
population, which contains many IFNc-producing CD8? T
cells following activation-mediated downregulation of
CD8 and (2) setting the gate wide enough from the
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Fig. 4 High background staining correlates with a low detection rate
in phase 3. The % of IFNc-producing cells in the negative control
sample (i.e., background) versus the detection of a response in the
corresponding stimulated sample is depicted for all donor–antigen
combinations (and all participants) in which a positive response
should have been detected (left; n = 50 stainings) or in the case that
low-frequency responses (as observed against FLU; n = 30 stainings)
should have been detected (right). The background was signiﬁcantly
lower in those donor–antigen combinations where a response was
detected
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Fig. 5 Harmonization of the gating strategy results in acceptable low
variation between laboratories participating in phase 3. The coefﬁ-
cient of variation (CV) value is given for the initial analysis of the in
silico gating ICS panel (white bars) and after instruction of three
participants, who then performed a re-analysis (black bars) only for
the positive reactive donor (D)-antigen (CMV or FLU) combination.
The CV values dropped after harmonization of the gating strategy
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123non-responding population to optimize the signal-to-noise
ratio. We conclude that harmonization of gating strategies
is the ﬁrst requirement before other parameters that inﬂu-
ence assay outcome can possibly be identiﬁed.
Although it is successful for harmonizing the IFNc-
ELISPOT assay and the ﬂow cytometric-based HLA mul-
timer assay [13], a simple 2-step method was not sufﬁcient
to harmonize the ICS assay. Central analyses of the data-
sets provided by the participants did not substantially
decrease the CV values indicating that in addition to the
gating strategy, there are protocol-related variables that
would beneﬁt from harmonization. The group of partici-
pants was too small to identify statistically signiﬁcant
effects, but this will be addressed in following CIP panels.
Indeed, for ELISPOT harmonization, we have previously
overcome this by the inclusion of a larger number of par-
ticipants; this could be combined with the use of one
standard operation procedure (SOP) in which systemati-
cally one variable is tested by all participants. In the ﬁeld of
HIV immune research, the analysis of speciﬁc T cells by
ICS is fully standardized by providing a SOP as well as the
peptides and lyophilized antibodies preﬁlled in 96-well
plates [7, 8, 26–28]. However, this is more difﬁcult and less
likely to be feasible in the ﬁeld of immunotherapy of
cancer where the antigens of interest vary between differ-
ent cancer types and between the many laboratories
involved. Nevertheless, recommendations for the gating
strategy can be given and are listed in Table 2, which were
demonstrated to provide some harmonization in this stage
of the ICS assay. Following these gating guidelines will
give the opportunity to be able to study and identify
parameters in the wet laboratory protocol inﬂuencing test
performance.
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Appendix
Participants of one or more ICS proﬁciency panel(s) of the
CIP:
1. E. Ka ¨mpgen, M. Wiesinger, S. Gross. Department of
Dermatology, University Hospital, Erlangen, Erlan-
gen, Germany.
2. G. Pawelec, E. Derhovanessian. Tu ¨bingen Ageing and
Tumour Immunology Group, Center for Medical
Research,UniversityofTu ¨bingen,Tu ¨bingen,Germany.
3. B. Seliger, D. Riemann. Institute of Medical Immu-
nology, Martin Luther University, Halle, Germany.
4. C. Britten, S. Attig. Mainz, Department of Internal
Medicine III, Johannes Gutenberg University, Mainz,
Germany.
5. K. Giannopoulos. Department of Experimental He-
matooncology, Medical University of Lublin, Lublin,
Poland.
6. H. Pohla. Laboratory of Tumour Immunology,
Ludwig-Maximilians-University, Munich, Germany.
7. M. Schmitt, A. Schmitt. Department of Cellular
Immunotherapy, University Clinic Heidelberg, Hei-
delberg, Germany.
8. C. Gouttefangeas, S. Attig, K. Laske. Department of
Immunology, Interfaculty Institute for Cell Biology,
Eberhard Karls University, Tu ¨bingen, Germany.
9. S. H. van der Burg, M.J.P. Welters. Department of
Clinical Oncology, Leiden University Medical Cen-
ter, Leiden, The Netherlands.
10. C. Ottensmeier, A. Mander, A. Cazaly. Cancer
Sciences Division, University Hospitals, Southamp-
ton, UK.
11. A. Paschen, F. Zhao. Department of Dermatology,
University Hospital Essen, Essen, Germany.
Table 2 Common ﬁndings/errors and recommendations for gating of ICS data
Findings/errors Recommendation and reason
1. Gating was done only on CD3-, CD4- and/or
CD8- high expressing cells
Include dim populations as these may contain cytokine-producing cells (cells can
downregulate co-receptor molecules upon activation)
2. Gate for cytokine-positive cells was set
through the cytokine-positive population
Include plots in your gating strategy for CD3? CD4- (in case of looking at cytokine-
producing CD8? T cells) or CD3? CD8- (for CD4) T cells to oversee all cytokine-
producing cells and be able to gate on the complete cytokine-positive population for
that certain T-cell type (so including dim)
3. Gate for cytokine-positive cells was set too
close to or included cytokine-negative cells
Set the gate far enough (but not too far) from the non-responding population to
decrease the background staining in the unstimulated sample and increase the
signal-to-noise ratio
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12312. A. Letsch. Department of Hematology, Oncology,
Charite ´ Campus Benjamin Franklin, Berlin, Ger-
many. C. Scheibenbogen. Department of Medical
Immunology, Charite ´ Campus Virchow-Klinikum,
Berlin, Germany.
13. F. Kern. Division of Medicine, Brighton and Sussex
Medical School, Brighton, UK.
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